Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEZOGIST
2019-001547-43Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastrointestinal stromal tumor (GIST) comparing Imatinib resumption + atezolizumab with Imatinib resumption alone (2 arms). Primary endpoint: Progression-free survival. Started Sep 2021; status: active.
02
Drugs
atezolizumabimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2019-001547-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001547-43.